Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a marked decline in cognition and memory function. Increasing evidence highlights the essential role of neuroinflammatory and immune-related molecules, including those produced at the brain barriers, on brain immune surveillance, cellular dysfunction and amyloid beta (Ab) pathology in AD. Therefore, understanding the response at the brain barriers may unravel novel pathways of relevance for the pathophysiology of AD. Herein, we focused on the study of the choroid plexus (CP), which constitutes the blood-cerebrospinal fluid barrier, in aging and in AD. Specifically, we used the PDGFB-APPSwInd (J20) transgenic mouse model of AD, which presents early memory decline and progressive Ab accumulation, and littermate age-matched wild-type (WT) mice, to characterize the CP transcriptome at 3, 5-6 and 11-12 months of age. The most striking observation was that the CP of J20 mice displayed an overall overexpression of type I interferon (IFN) response genes at all ages. Moreover, J20 mice presented a high expression of type II IFN genes in the CP at 3 months, which became lower than WT at 5-6 and 11-12 months. Importantly, along with a marked memory impairment and increased glial activation, J20 mice also presented a similar overexpression of type I IFN genes in the dorsal hippocampus at 3 months. Altogether, these findings provide new insights on a possible interplay between type I and II IFN responses in AD and point to IFNs as targets for modulation in cognitive decline.
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Introduction
Alzheimer's disease (AD) is the most prevalent form of dementia and is predicted to affect eighty million people worldwide by 2040 (Ballard et al., 2011; Querfurth and LaFerla, 2010) . The major constraint of AD patients is the severe loss of cognitive abilities (Ballard et al., 2011) . Moreover, this neurodegenerative disease is characterized by two main brain pathological hallmarks: the extracellular deposition of amyloid beta (Ab) peptides, in the form of senile plaques, and the formation of intracellular neurofibrillary tangles, as a result of increased aggregation of hyperphosphorylated Tau protein (Gotz et al., 2001; Hardy and Selkoe, 2002; Lewis et al., 2001; Scheuner et al., 1996) . The amyloidogenic hypothesis of AD considers that amyloid pathology may result from increased Ab production, through the amyloidogenic processing of the amyloid precursor protein (APP), and/or decreased excretion of Ab out of the brain (Hardy and Selkoe, 2002; Roberson and Mucke, 2006) . In fact, oligomerization of Ab peptides in the brain has been described as an early pathogenic event that is responsible for behavior alterations (Mucke et al., 2000; Palop and Mucke, 2010) . However, regardless of the attention given to increased Ab formation and toxicity in the brain, neuroinflammation is also recognized as an early and essential mediator of brain pathology and behavior alteration in AD (Lucin and Wyss-Coray, 2009; Wyss-Coray, 2006) . In this context, two relevant emerging concepts should be considered: (I) the age-associated changes in the blood composition and (II) the levels/ratio of type I and II interferon (IFN) cytokines. Regarding the first concept, recent observations showed the involvement of the systemic milieu in memory formation and the role of specific inflammatory molecules in age-related decreased synaptic plasticity and memory function (Baruch et al., 2013; Villeda et al., 2011) . Regarding the second concept, an enhanced type I IFN signaling at the brain barriers, and
